Third-line therapy

The Lancet HIV Editor Peter Hayward talks to Beatriz Grinsztejn (Evandro Chagas National Institute of Infectious Diseases, Fiocruz, Rio de Janeiro, Brazil) about ACTG A5288, an international, multiarm trial investigating management of second-line treatment failure Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com...